Top

Published in:

01-06-2021 | Graft-Versus-Host Disease | Review Article

Immunomodulating functions of human leukocyte antigen-G and its role in graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

Authors: Xiaoyin Bu, Jinman Zhong, Weiru Li, Shengchun Cai, Ya Gao, Baohong Ping

Published in: Annals of Hematology | Issue 6/2021

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative therapeutic strategy to treat several hematological malignancies and non-hematological malignancies. However, graft-versus-host disease (GVHD) is a frequent and serious transplant-related complication which dramatically restrains the curative effect of allo-HSCT and a significant cause of morbidity and mortality in allogeneic HCT recipients. Effective prevention of GVHD mainly depends on the induction of peripheral immune tolerance. Human leukocyte antigen-G (HLA-G) is a non-classical MHC class I molecule with a strong immunosuppressive function, which plays a prominent role in immune tolerance. HLA-G triggers different reactions depending on the activation state of the immune cells and system. It also exerts a long-term immune tolerance mechanism by inducing regulatory cells. In this present review, we demonstrate the immunomodulatory properties of human leukocyte antigen-G and highlight the role of HLA-G as an immune regulator of GVHD. Furthermore, HLA-G could also serve as a good predictor of GVHD and represent a new therapeutic target for GVHD.

Rodrigues KS, Oliveira-Ribeiro C, de Abreu Fiuza Gomes S, Knobler R (2018) Cutaneous graft-versus-host disease: diagnosis and treatment. Am J Clin Dermatol 19(1):33–50. https://doi.org/10.1007/s40257-017-0306-9CrossRef

Zhang L, Chu J, Yu J, Wei W (2016) Cellular and molecular mechanisms in graft-versus-host disease. J Leukoc Biol 99(2):279–287. https://doi.org/10.1189/jlb.4RU0615-254RRCrossRefPubMed

Curigliano G, Criscitiello C, Gelao L, Goldhirsch A (2013) Molecular pathways: human leukocyte antigen G (HLA-G). Clin Cancer Res 19(20):5564–5571. https://doi.org/10.1158/1078-0432.CCR-12-3697CrossRefPubMed

Morandi F, Rizzo R, Fainardi E, Rouas-Freiss N, Pistoia V (2016) Recent advances in our understanding of HLA-G biology: lessons from a wide spectrum of human diseases. J Immunol Res 2016:1–14. https://doi.org/10.1155/2016/4326495CrossRef

Amodio G, Comi M, Tomasoni D, Gianolini ME, Rizzo R, LeMaoult J, Roncarolo MG, Gregori S (2015) HLA-G expression levels influence the tolerogenic activity of human DC-10. Haematologica 100(4):548–557. https://doi.org/10.3324/haematol.2014.113803CrossRefPubMedPubMedCentral

Gregori S, Tomasoni D, Pacciani V, Scirpoli M, Battaglia M, Magnani CF, Hauben E, Roncarolo MG (2010) Differentiation of Type 1 T Regulatory Cells (Tr1) by Tolerogenic DC-10 Requires the IL-10-dependent ILT4/HLA-G Pathway. Blood 116(6):935–944. https://doi.org/10.1182/blood-2009-07-234872CrossRefPubMed

Carosella ED, Rouas-Freiss N, Roux DT, Moreau P, LeMaoult J (2015) HLA-G: An immune checkpoint molecule. Adv Immunol 127:33–144. https://doi.org/10.1016/bs.ai.2015.04.001CrossRefPubMed

Le Maux A, Noël G, Birebent B, Grosset J, Vu N, De Guibert S et al (2008) Soluble human leucocyte antigen-G molecules in peripheral blood haematopoietic stem cell transplantation: a specific role to prevent acute graft-versus-host disease and a link with regulatory T cells. Clin Exp Immunol 152(1):50–56. https://doi.org/10.1111/j.1365-2249.2008.03598.xCrossRefPubMedPubMedCentral

Liu H, Chen Y, Xuan L, Wu X, Zhang Y, Fan Z, Huang F, Zhang X, Jiang Q, Sun J, Liu Q (2013) Soluble human leukocyte antigen g molecule expression in allogeneic hematopoietic stem cell transplantation: good predictor of acute graft-versus-host disease. Acta Haematol 130(3):160–168. https://doi.org/10.1159/000350488CrossRefPubMed

10.

Biedroń M, Rybka J, Wróbel T, Prajs I, Poręba R, Kuliczkowski K (2015) The role of soluble HLA-G and HLA-G receptors in patients with hematological malignancies after allogeneic stem cell transplantation. Med Oncol 32:219. https://doi.org/10.1007/s12032-015-0664-1CrossRefPubMed

11.

Kordelas L, Da Silva NF, Wagner B, Ditschkowski M, Liebregts T, Lindemann M et al (2018) Elevated soluble human leukocyte antigen G levels in patients after allogeneic stem cell transplantation are associated with less severe acute and chronic graft-versus-host disease. Bone Marrow Transplant 53(9):1149–1156. https://doi.org/10.1038/s41409-018-0145-1CrossRefPubMed

12.

Nomura S, Ito T, Katayama Y, Ota S, Hayashi K, Fujita S, Satake A, Ishii K (2019) Effects of recombinant thrombomodulin therapy and soluble human leukocyte antigen-G levels during hematopoietic stem cell transplantation. Transpl Immunol 53:28–33. https://doi.org/10.1016/j.trim.2018.12.001CrossRefPubMed

13.

Donadi EA, Castelli EC, Arnaiz-Villena A, Roger M (2011) Implications of the polymorphism of HLA-G on its function, regulation, evolution and disease association. Cell Mol Life Sci 68(3):369–395. https://doi.org/10.1007/s00018-010-0580-7CrossRefPubMed

14.

Pistoia V, Morandi F, Wang X, Ferrone S (2007) Soluble HLA-G: are they clinically relevant? Semin Cancer Biol 17(6):469–479CrossRefPubMedPubMedCentral

15.

Bai Y, Liang J, Liu W, Wang F, Li C (2020) Possible roles of HLA-G regulating immune cells in pregnancy and endometrial diseases via KIR2DL4. J Reprod Immunol 142:103176. https://doi.org/10.1016/j.jri.2020.103176CrossRefPubMed

16.

Li X, Sheng Z, Sun Y, Wang Y, Xu M, Zhang Z et al (2018) Human leukocyte antigen-G upregulates immunoglobulin-like transcripts and corrects dysfunction of immune cells in immune thrombocytopenia. Haematologica 2020:204040–204781. https://doi.org/10.3324/haematol.2018.204040CrossRef

17.

Rebmann V, Busemann A, Lindemann M, Grosse-Wilde H (2003) Detection of HLA-G5 secreting cells. Hum Immunol 64(11):1017–1024. https://doi.org/10.1016/j.humimm.2003.08.354CrossRefPubMed

18.

Lazarte J, Adamson MB, Tumiati LC, Delgado DH (2018) 10-year experience with HLA-G in heart transplantation. Hum Immunol 79(8):587–593. https://doi.org/10.1016/j.humimm.2018.05.003CrossRefPubMed

19.

González A, Rebmann V, LeMaoult J, Horn PA, Carosella ED, Alegre E (2012) The immunosuppressive molecule HLA-G and its clinical implications. Crit Rev Clin Lab Sci 49(3):63–84. https://doi.org/10.3109/10408363.2012.677947CrossRefPubMed

20.

Blazar BR, Murphy WJ, Abedi M (2012) Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol 12(6):443–458. https://doi.org/10.1038/nri3212CrossRefPubMedPubMedCentral

21.

Li A, Abraham C, Wang Y, Zhang Y (2020) New insights into the basic biology of acute graft-versus-host-disease. Haematologica 105(11):2540–2549. https://doi.org/10.3324/haematol.2019.240291CrossRefPubMedPubMedCentral

22.

Amodio G, Sales DAR, Gregori S (2014) New insights into HLA-G mediated tolerance. Tissue Antigens 84(3):255–263. https://doi.org/10.1111/tan.12427CrossRefPubMed

23.

Morandi F, Ferretti E, Bocca P, Prigione I, Raffaghello L, Pistoia V (2010) A novel mechanism of soluble HLA-G mediated immune modulation: downregulation of T Cell chemokine receptor expression and impairment of chemotaxis. PLoS One 5(7):e11763. https://doi.org/10.1371/journal.pone.0011763CrossRefPubMedPubMedCentral

24.

Pankratz S, Bittner S, Herrmann AM, Schuhmann MK, Ruck T, Meuth SG et al (2016) CD4+HLA-G+ regulatory T cells: molecular signature and pathophysiological relevance. Hum Immunol 77(9):727–733. https://doi.org/10.1016/j.humimm.2016.01.016CrossRefPubMed

25.

Pankratz S, Bittner S, Herrmann AM, Schuhmann MK, Ruck T, Meuth SG, Wiendl H (2014) Human CD4+HLA-G+ regulatory T cells are potent suppressors of graft-versus-host disease in vivo. FASEB J 28(8):3435–3445. https://doi.org/10.1096/fj.14-251074CrossRefPubMed

26.

Rebmann V, Nardi FDS, Wagner B, Horn PA (2014) HLA-G as a tolerogenic molecule in transplantation and pregnancy. J Immunol Res 2014:297073–297016. https://doi.org/10.1155/2014/297073CrossRefPubMedPubMedCentral

27.

Contini P, Ghio M, Merlo A, Poggi A, Indiveri F, Puppo F (2005) Apoptosis of antigen-specific T lymphocytes upon the engagement of CD8 by soluble HLA class I molecules is Fas ligand/Fas mediated: evidence for the involvement of p56lck, calcium calmodulin kinase II, and Calcium-independent protein kinase C signaling pathways and for NF-kappaB and NF-AT nuclear translocation. J Immunol 175(11):7244–7254. https://doi.org/10.4049/jimmunol.175.11.7244CrossRefPubMed

28.

Chen Y, Lu D, Churov A, Fu R (2020) Research progress on NK cell receptors and their signaling pathways. Mediat Inflamm 2020:6437057–6437014. https://doi.org/10.1155/2020/6437057CrossRef

29.

Zaghi E, Calvi M, Marcenaro E, Mavilio D, Di Vito C (2019) Targeting NKG2A to elucidate natural killer cell ontogenesis and to develop novel immune-therapeutic strategies in cancer therapy. J Leukoc Biol 105(6):1243–1251. https://doi.org/10.1002/JLB.MR0718-300RCrossRefPubMed

30.

Schmitt J, Eckardt S, Schlegel PG, Sirén A, Bruttel VS, McLaughlin KJ et al (2015) Human parthenogenetic embryonic stem cell-derived neural stem cells express HLA-G and show unique resistance to NK cell-mediated killing. Mol Med 21(1):185–196. https://doi.org/10.2119/molmed.2014.00188CrossRefPubMedPubMedCentral

31.

Zhang W, Xu D, Liu D, Li Y, Ruan Y, Lin A et al (2014) HLA-G1 and HLA-G5 isoforms have an additive effect on NK cytolysis. Hum Immunol 75(2):182–189. https://doi.org/10.1016/j.humimm.2013.11.001CrossRefPubMed

32.

Zhao L, Purandare B, Zhang J, Hantash BM (2013) β2-Microglobulin-free HLA-G activates natural killer cells by increasing cytotoxicity and proinflammatory cytokine production. Hum Immunol 74(4):417–424. https://doi.org/10.1016/j.humimm.2012.11.022CrossRefPubMed

33.

Morandi F, Ferretti E, Castriconi R, Dondero A, Petretto A, Bottino C, Pistoia V (2011) Soluble HLA-G dampens CD94/NKG2A expression and function and differentially modulates chemotaxis and cytokine and chemokine secretion in CD56bright and CD56dim NK cells. Blood 118(22):5840–5850. https://doi.org/10.1182/blood-2011CrossRefPubMed

34.

Banerjee PP, Pang L, Soldan SS, Miah SM, Eisenberg A, Maru S, Waldman A, Smith EA, Rosenberg-Hasson Y, Hirschberg D, Smith A, Ablashi DV, Campbell KS, Orange JS (2019) KIR2DL4-HLAG interaction at human NK Cell-oligodendrocyte interfaces regulates IFN-γ-mediated effects. Mol Immunol 115:39–55. https://doi.org/10.1016/j.molimm.2018.09.027CrossRefPubMed

35.

Le Page MEL, Goodridge JP, John E, Christiansen FT, Witt CS (2014) Killer Ig-like receptor 2DL4 does not mediate NK cell IFN-gamma responses to soluble HLA-G preparations. J Immunol 192(2):732–740. https://doi.org/10.4049/jimmunol.1301748CrossRefPubMed

36.

Silva ILD, Montero-Montero L, Ferreira E, Quintanilla M (2018) New insights into the role of Qa-2 and HLA-G Non-classical MHC-I complexes in malignancy. Front Immunol 9:2894. https://doi.org/10.3389/fimmu.2018.02894CrossRefPubMedPubMedCentral

37.

Liang S, Ristich V, Arase H, Dausset J, Carosella ED, Horuzsko A (2008) Modulation of dendritic cell differentiation by HLA-G and ILT4 requires the IL-6--STAT3 signaling pathway. Proc Natl Acad Sci U S A 105(24):8357–8362. https://doi.org/10.1073/pnas.0803341105CrossRefPubMedPubMedCentral

38.

Naji A, Menier C, Morandi F, Agaugué S, Maki G, Ferretti E, Bruel S, Pistoia V, Carosella ED, Rouas-Freiss N (2014) Binding of HLA-G to ITIM-bearing Ig-like transcript 2 receptor suppresses B cell responses. J Immunol 192(4):1536–1546. https://doi.org/10.4049/jimmunol.1300438CrossRefPubMed

39.

LeMaoult J, Zafaranloo K, Le Danff C, Carosella ED (2005) HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells. FASEB J 19(6):662–664. https://doi.org/10.1096/fj.04-1617fjeCrossRefPubMed

40.

Schwich E, Hò GT, LeMaoult J, Bade-Döding C, Carosella ED, Horn PA et al (2020) Soluble HLA-G and HLA-G bearing extracellular vesicles affect ILT-2 positive and ILT-2 negative CD8 T cells complementary. Front Immunol 11:2046. https://doi.org/10.3389/fimmu.2020.02046CrossRefPubMedPubMedCentral

41.

Selmani Z, Naji A, Zidi I, Favier B, Gaiffe E, Obert L, Borg C, Saas P, Tiberghien P, Rouas-Freiss N, Carosella ED, Deschaseaux F (2008) Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+regulatory T cells. Stem Cells 26(1):212–222. https://doi.org/10.1634/stemcells.2007-0554CrossRefPubMed

42.

Obregon C, Kumar R, Pascual MA, Vassalli G, Golshayan D (2017) Update on dendritic cell-induced immunological and clinical tolerance. Front Immunol 8:1514. https://doi.org/10.3389/fimmu.2017.01514CrossRefPubMedPubMedCentral

43.

Xu D, Shi W, Zhang T, Lv H, Li J, Lin A et al (2016) Elevation of HLA-G-expressing DC-10 cells in patients with gastric cancer. Hum Immunol 77(9):800–804. https://doi.org/10.1016/j.humimm.2016.01.003CrossRefPubMed

44.

LeMaoult J, Caumartin J, Daouya M, Switala M, Rebmann V, Arnulf B, Carosella ED (2015) Trogocytic intercellular membrane exchanges among hematological tumors. J Hematol Oncol 8:24. https://doi.org/10.1186/s13045-015-0114-8CrossRefPubMedPubMedCentral

45.

Alegre E, Howangyin K, Favier B, Baudhuin J, Lesport E, Daouya M et al (2010) Membrane redistributions through multi-intercellular exchanges and serial trogocytosis. Cell Res 20(11):1239–1251. https://doi.org/10.1038/cr.2010.136CrossRefPubMed

46.

Min C (2011) The pathophysiology of chronic graft-versus-host disease: the unveiling of an enigma. Korean J Hematol 46(2):80–87. https://doi.org/10.5045/kjh.2011.46.2.80CrossRefPubMedPubMedCentral

47.

Yehudai-Ofir D, Henig I, Zuckerman T (2020) Aberrant B cells, autoimmunity and the benefit of targeting B cells in chronic graft-versus-host disease. Autoimmun Rev 19(4):102493. https://doi.org/10.1016/j.autrev.2020.102493CrossRefPubMed

48.

Zeiser R (2019) Advances in understanding the pathogenesis of graft-versus-host disease. Br J Haematol 187(5):563–572. https://doi.org/10.1111/bjh.16190CrossRefPubMed

49.

D'Almeida TC, Sadissou I, Sagbohan M, Milet J, Avokpaho E, Gineau L et al (2019) High level of soluble human leukocyte antigen (HLA)-G at beginning of pregnancy as predictor of risk of malaria during infancy. Sci Rep 9(1):9160. https://doi.org/10.1038/s41598-019-45688-wCrossRefPubMedPubMedCentral

50.

Lila N, Amrein C, Guillemain R, Chevalier P, Latremouille C, Fabiani JN et al (2002) Human leukocyte antigen-G expression after heart transplantation is associated with a reduced incidence of rejection. Circulation 105(16):1949–1954. https://doi.org/10.1161/01.cir.0000015075.89984.46CrossRefPubMed

51.

Crispim JC, Duarte RA, Soares CP, Costa R, Silva JS, Mendes-Júnior CT et al (2008) Human leukocyte antigen-G expression after kidney transplantation is associated with a reduced incidence of rejection. Transpl Immunol 18(4):361–367. https://doi.org/10.1016/j.trim.2007.10.010CrossRefPubMed

52.

Waterhouse M, Duque-Afonso J, Wäsch R, Bertz H, Finke J (2013) Soluble HLA-G molecules and HLA-G 14–base pair polymorphism after allogeneic hematopoietic cell transplantation. Transplant Proc 45(1):397–401. https://doi.org/10.1016/j.transproceed.2012.05.073CrossRefPubMed

53.

Chen XY, Yan WH, Lin A, Xu HH, Zhang JG, Wang XX (2008) The 14 bp deletion polymorphisms in HLA-G gene play an important role in the expression of soluble HLA-G in plasma. Tissue Antigens 72(4):335–341. https://doi.org/10.1111/j.1399-0039.2008.01107.xCrossRefPubMed

54.

Martelli-Palomino G, Pancotto JA, Muniz YC, Mendes-Junior CT, Castelli EC, Massaro JD, Krawice-Radanne I, Poras I, Rebmann V, Carosella ED, Rouas-Freiss N, Moreau P, Donadi EA (2013) Polymorphic sites at the 3' untranslated region of the HLA-G gene are associated with differential Hla-G soluble Levels in the Brazilian and French population. PLoS One 8(10):e71742. https://doi.org/10.1371/journal.pone.0071742CrossRefPubMedPubMedCentral

55.

Di Cristofaro J, El Moujally D, Agnel A, Mazières S, Cortey M, Basire A et al (2013) HLA-G haplotype structure shows good conservation between different populations and good correlation with high, normal and low soluble HLA-G expression. Hum Immunol 74(2):203–206. https://doi.org/10.1016/j.humimm.2012.10.027CrossRefPubMed

56.

Boukouaci W, Busson M, Fortier C, Amokrane K, de Latour RP, Robin M, Krishnamoorthy R, Toubert A, Charron D, Socié G, Tamouza R (2011) Association of HLA-G low expressor genotype with severe acute graft-versus-host disease after sibling bone marrow transplantation. Front Immunol 2:74. https://doi.org/10.3389/fimmu.2011.00074CrossRefPubMedPubMedCentral

57.

La Nasa G, Littera R, Locatelli F, Lai S, Alba F, Caocci G et al (2007) The human leucocyte antigen-G 14-basepair polymorphism correlates with graft-versus-host disease in unrelated bone marrow transplantation for thalassaemia. Br J Haematol 139(2):284–288. https://doi.org/10.1111/j.1365-2141.2007.06779.xCrossRefPubMed

58.

Sizzano F, Testi M, Zito L, Crocchiolo R, Troiano M, Mazzi B, Turchiano G, Torchio M, Pultrone C, Gregori S, Chiesa R, Gaziev J, Sodani P, Marktel S, Amoroso A, Roncarolo MG, Lucarelli G, Ciceri F, Andreani M, Fleischhauer K (2012) Genotypes and haplotypes in the 3' untranslated region of the HLA-G gene and their association with clinical outcome of hematopoietic stem cell transplantation for beta-thalassemia. Tissue Antigens 79(5):326–332. https://doi.org/10.1111/j.1399-0039.2012.01862.xCrossRefPubMed

59.

Chiusolo P, Bellesi S, Piccirillo N, Giammarco S, Marietti S, De Ritis D et al (2012) The role of HLA – G 14-bp polymorphism in allo-HSCT after short-term course MTX for GvHD prophylaxis. Bone Marrow Transplant 47(1):120–124. https://doi.org/10.1038/bmt.2011.40CrossRefPubMed

60.

Le Blanc K, Rasmusson I, Sundberg B, Götherström C, Hassan M, Uzunel M et al (2004) Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363(9419):1439–1441. https://doi.org/10.1016/S0140-6736(04)16104-7CrossRefPubMed

61.

Yi HG, Yahng S, Kim I, Lee J, Min C, Kim JH et al (2016) Allogeneic clonal mesenchymal stem cell therapy for refractory graft-versus-host disease to standard treatment: a phase I study. Korean J Physiol Pharmacol 20(1):63–67. https://doi.org/10.4196/kjpp.2016.20.1.63CrossRefPubMed

62.

Deschaseaux F, Gaillard J, Langonné A, Chauveau C, Naji A, Bouacida A, Rosset P, Heymann D, de Pinieux G, Rouas-Freiss N, Sensébé L (2013) Regulation and function of immunosuppressive molecule human leukocyte antigen G5 in human bone tissue. FASEB J 27(8):2977–2987. https://doi.org/10.1096/fj.13-227264CrossRefPubMed

63.

Kordelas L, Rebmann V, Ludwig A, Radtke S, Ruesing J, Doeppner TR et al (2014) MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease. Leukemia 28(4):970–973. https://doi.org/10.1038/leu.2014.41CrossRefPubMed

64.

Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S, Negrin RS (2003) CD4+CD25+ regulatory T cells preserve graft-versus- tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 9(9):1144–1150. https://doi.org/10.1038/nm915CrossRefPubMed

65.

Stamou P, Marioli D, Patmanidi AL, Sgourou A, Vittoraki A, Theofani E, Pierides C, Taraviras S, Costeas PA, Spyridonidis A (2017) Simple in vitro generation of human leukocyte antigen-G-expressing T-regulatory cells through pharmacological hypomethylation for adoptive cellular immunotherapy against graft-versus-host disease. Cytotherapy 19(4):521–530. https://doi.org/10.1016/j.jcyt.2017.01.004CrossRefPubMed

66.

Lam AJ, Hoeppli RE, Levings MK (2017) Harnessing advances in T regulatory cell biology for cellular therapy in transplantation. Transplantation 101(10):2277–2287. https://doi.org/10.1097/TP.0000000000001757CrossRefPubMed

67.

Favier B, HoWangYin K, Wu J, Caumartin J, Daouya M, Horuzsko A et al (2011) Tolerogenic function of dimeric forms of HLA-G recombinant proteins: a comparative study in vivo. PLoS One 6(7):e21011. https://doi.org/10.1371/journal.pone.0021011CrossRefPubMedPubMedCentral

68.

LeMaoult J, Daouya M, Wu J, Loustau M, Horuzsko A, Carosella ED (2013) Synthetic HLA-G proteins for therapeutic use in transplantation. FASEB J 27(9):3643–3651. https://doi.org/10.1096/fj.13-228247CrossRefPubMedPubMedCentral

Title: Immunomodulating functions of human leukocyte antigen-G and its role in graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
Authors: Xiaoyin Bu
Jinman Zhong
Weiru Li
Shengchun Cai
Ya Gao
Baohong Ping
Publication date: 01-06-2021
Publisher: Springer Berlin Heidelberg
Keywords: Graft-Versus-Host Disease
Graft-Versus-Host Disease
Stem Cell Transplantation
Stem Cell Transplantion
Stem Cell Transplantation
Published in: Annals of Hematology / Issue 6/2021
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-021-04486-z

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Immunomodulating functions of human leukocyte antigen-G and its role in graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2021

Tissue factor–bearing microparticles are a link between acute promyelocytic leukemia cells and coagulation activation: a human subject study

A case of transplantation-associated thrombotic microangiopathy with autopsy-proven fatal myocardial ischemia after allogeneic hematopoietic stem cell transplantation

Stanozolol for the treatment of anemic lower-risk myelodysplastic syndromes without del(5q) after failure of epoetin alfa: findings from a retrospective study

Prognostic assessment for chronic myelomonocytic leukemia in the context of the World Health Organization 2016 proposal: a multicenter study of 280 patients

Paraneoplastic aortitis in a patient with relapsed multiple myeloma successfully treated with daratumumab, bortezomib and dexamethasone

Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO/DGHO)

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page